The UK’s Horizon trial will test a vaccine against the Epstein-Barr virus (EBV), linked to multiple sclerosis, aiming to train the immune system and explore a potential new treatment for MS.
Prof Dr Susanne M Bailer, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, explains the possibilities of an oncolytic virus platform technology.
Richard Armstrong, head of registries at NEC Software Solutions UK, puts real-world evidence under the microscope and examines how, as our population ages it has the power to speed up medical interventions at scale.
Led by Yale Cancer Center, new research shows that enfortumab vedotin is an effective alternative for patients with muscle-invasive bladder cancer (MIBC)
Professor Freimut Schliess, Director of Science & Innovation, at the Profil Institut für Stoffwechselforschung GmbH, illustrates how dissipating initial scepticism of digital health technologies makes for a thrilling challenge for regulators, manufacturers and clinical researchers alike.
McLean Hospital’s Clinical and Translational Pain Research Laboratory is one of five institutions splitting a $1.67 million NIH grant - the research will examine any links between the menstrual cycle and the COVID vaccine.
